ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
283 | (±¹¿Ü)SCIE | High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer |
282 | (±¹¿Ü)SCIE | Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer |
281 | (±¹¿Ü)SCIE | Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients |
280 | (±¹¿Ü)SCIE | Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach |
279 | (±¹¿Ü)SCIE | Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study |
278 | (±¹¿Ü)SCIE | Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events |
277 | (±¹¿Ü)SCIE | Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors |
276 | (±¹¿Ü)SCIE | Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis |
275 | (±¹³»)SCI | A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients |
274 | (±¹³»)KCI | Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report |
Copyright ¨Ï chamc, All rights reserved.